Tag Archives: FiercePharma

Healthcare stocks bounce back Friday after really messy week, but still licking their wounds from recent global selloff.

After having their worst week in recent memory, with the NASDAQ HealthCare Index (IXHC) now down 8.6% since just Sept. 28, some healthcare stocks nonetheless blossomed with stupendous upswings. But… Read more »

Korean push into biotech space meant to challenge China, as ViroMed buys US plant for new gene-therapy development. High risk/reward bet, only for the brave.

The News: ViroMed Co. Ltd., the Korean biotech, has seen companies miss out on approvals for novel therapies because the FDA had problems with their manufacturing processes. With its first treatment… Read more »

ViiV Healthcare’s success with monthly combo HIV med making Gilead sweat over its HIV franchise. After World Cup fiasco, England chasing California in $$$$/rep race.

The News: GlaxoSmithKline PLC’s (London) ViiV Healthcare unit now has results to support a two-drug monthly injection co-developed with Johnson & Johnson (New Brunswick NJ) as it pushes ahead with its ambition… Read more »

Solution to China’s vaccine scandal now in the hands of rising blockchain maven VeChain. Buy a few tokens?

The News: A new production scandal has undermined Chinese citizens’ confidence in domestically made vaccines, and the tech community is suggesting the solution may lie in a highly touted technology: blockchain…. Read more »

Vertex says it would be NICE if England upped its offer for new CF drugs. Meanwhile, short lesson on how US could quickly lower its pharma prices, too.

The News: Vertex Pharma CEO Jeffrey Leiden’s move earlier this month to pressure England’s prime minister Theresa May on drug prices seems to have set some wheels in motion. After… Read more »

Wondering why some of your Pharma shares keep going up? Thank Trump’s tax “reform;” no, really.

The News: The drug industry has taken heat from patient advocates and a US senator for handing out its tax savings to shareholders instead of using its windfall to help patients… Read more »

Doctors reliance on pharmas increasing, while general public trusts supermarkets more. What’s wrong with this picture?

The News: When it comes to pharma partners, doctors prefer quality digital content, according to a new report. While that comes as no surprise and makes sense, new research shows… Read more »

Pfizer, Merck’s Bavencio flop illustrative of shattered Pharma model. Is industry’s collapse just around the corner?

The News: Pfizer Inc. (NYC) and its German part­ner Merck KGaA (Darmstadt) have run into a brick wall in their race to ex­pand the mar­ket for their PD-L1 check­point inhibitor Baven­cio… Read more »

Alarming study concludes most new, pricey cancer drugs don’t work; why are we just hearing about this?

The News: Researchers said only half of the cancer drugs approved by European regulators in the past few years have shown to help patients. Many of the drugs were approved… Read more »

Catabasis soars on fresh Duchenne trial data, proving biotech melt-up still in progress; but for how much longer?

The News: Recuperating from a trial flop involving its lead drug for Duchenne muscular dystrophy, Catabasis Pharmaceuticals Inc. (Cambridge MA) is charging ahead with a late-stage study, hyping new data… Read more »